- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
July 21, 2023 updated by: Nicole Fram M.D.
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
Study Overview
Status
Recruiting
Conditions
Detailed Description
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt Treating Pain, and inflamMation Following Cataract Surgery Compared to Topical Prednisolone Acetate 1%.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nicole R Fram, M.D.
- Phone Number: 310-229-1220
- Email: nicfram@yahoo.com
Study Contact Backup
- Name: Orly Shiler
- Phone Number: 310-229-1220
- Email: orlyjr@inorbit.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90067
- Recruiting
- Advanced Vision Care
-
Principal Investigator:
- Nicole Fram, MD
-
Contact:
- Orly Shiler
- Phone Number: 310-229-1220
- Email: orlyjr@inorbit.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed with clinically significant cataract and are planning to undergo non-complicated Clear Cornea Incision Cataract Extraction with Posterior Capsule IntraOcular Lens in one or both eyes
- Are willing and able to comply with clinic visits and study related procedures
- Are willing and able to sign the informed consent form
Exclusion Criteria:
- Under the age of 18 at the time of signing the Informed Consent Form
- Pregnant or planning to become pregnant during the trial period
- Have visual acuity potential of less than 20/30 as recorded by a Retinal Acuity Meter or Potential Acuity Meter glare testing
- Have active infectious systemic disease
- Have active infectious ocular or extraocular disease
- Have punctal plug in the study eye
- Have obstructed nasolacrimal duct in the study eye(s) (dacryocystitus)
- Have known hypersensitivity to dexamethasone or are a known steroid responder
- Have a history of ocular inflammation or macular edema
- Has history of Laser Vision Correction (LASIK, PhotoRefractive Keratectomy) in the operated eye
- Are currently being treated with immunomodulating agents in the study eye
- Are currently being treated with immunosuppressants and/or oral steroids
- Are currently being treated with corticosteroid implant (i.e Ozurdex)
- Have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye
- Have a history of complete punctal occlusion in one or both punctum
- Currently using topical ophthalmic steroid medications
- Are unwilling or unable to comply with the study protocol
- Are determined by the Investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular disease/abnormality) if the health of the subject or the validity of the study outcomes may be compromised by the subject's enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1 - Cataract surgery gtt regimen per SOC
Following cataract surgery (without Dextenza 0.4mg insert) patients will receive: Prednisolone Acetate 1% QID X 2 Weeks, then BID x 2 weeks and stop / Prolensa 0.07% QD X 4 Weeks and stop.
|
Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.
Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
|
Experimental: Arm 2 - Cataract surgery with Dextenza and less frequency of gtt regimen
Following cataract surgery with DEXTENZA 0.4mg insert, patients will receive: Prolensa 0.07% QD X 4 Weeks and stop
|
Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in anterior chamber inflammation (Cell and Flare) scores
Time Frame: Assessed on Days 1,7,30,90
|
Measured by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1.
0-4 score scale, higher scores (4) mean a worse outcome.
|
Assessed on Days 1,7,30,90
|
Mean change in pain score
Time Frame: Assessed on Day 1,7, 30 and 90
|
Measured with the visual analog scale (VAS); between 0 and 100; 0 meaning no pain and 100 meaning worst pain possible
|
Assessed on Day 1,7, 30 and 90
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual outcome (Best Corrected Visual Acuity)
Time Frame: Assessed on Day 1,7, 30 and 90
|
Measured by ETDRS (Early Treatment Diabetic Retinopathy Study) chart.
0-70 letter read score.
higher scores mean a better outcome.
|
Assessed on Day 1,7, 30 and 90
|
Absence of CME (Cystoid Macular Edema)
Time Frame: Assessed on Day 90
|
Measured by OCT (Optical Coherence Tomography)
|
Assessed on Day 90
|
Mean change in corneal staining
Time Frame: Assessed on Day 7, 30 and 90
|
measured by the National Eye Institute 0-4 score scale, higher scores (4) mean a worse outcome.
|
Assessed on Day 7, 30 and 90
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety endpoint: corneal or retinal edema
Time Frame: Assessed throughout 90-day study period
|
Measured by slit lamp examination and supporting imaging and testing such as Pachymetry measured in micrometer (μm) or Macular (Optical Coherence Tomography)
|
Assessed throughout 90-day study period
|
Safety endpoint: Signs of Rebound Iritis
Time Frame: Assessed throughout 90-day study period
|
Measured by slit lamp examination and scored by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1, (0-4 score scale) higher scores (4) mean a worse outcome.
(specifically sub-grouped Blue vs. Brown eyed subjects)
|
Assessed throughout 90-day study period
|
Safety endpoint: Change in IOP (IntraOcular Pressure) initiating rescue medications
Time Frame: Assessed throughout 90-day study period
|
Measured by Applanation in millimeter Hg(Mercury), higher then 22mm Hg or lower then 10mm Hg mean a worse outcome and a need for rescue.
|
Assessed throughout 90-day study period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nicole R Fram, M.D., Advanced Vision Care
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Greenwood MD, Gorham RA, Boever KR. A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK). Clin Ophthalmol. 2020 Aug 6;14:2223-2228. doi: 10.2147/OPTH.S265311. eCollection 2020.
- Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019 Feb;45(2):204-212. doi: 10.1016/j.jcrs.2018.09.023. Epub 2018 Oct 24. Erratum In: J Cataract Refract Surg. 2019 Jun;45(6):895.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2023
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
November 8, 2022
First Submitted That Met QC Criteria
November 15, 2022
First Posted (Actual)
November 23, 2022
Study Record Updates
Last Update Posted (Estimated)
July 24, 2023
Last Update Submitted That Met QC Criteria
July 21, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Lens Diseases
- Corneal Diseases
- Inflammation
- Macular Edema
- Cataract
- Edema
- Corneal Edema
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Pharmaceutical Solutions
- Dexamethasone
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
- Ophthalmic Solutions
Other Study ID Numbers
- AVC-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anterior Chamber Inflammation
-
Bucci Laser Vision InstituteAllerganCompletedPost Operative Anterior Chamber Inflammation (Flare)United States
-
Istanbul UniversityCompletedAnterior Chamber Inflammation | Cornea | Refractive SurgeryTurkey
-
Yune ZhaoUnknownPhacoemulsification | Anterior Chamber Parameters | Anterior Segment Swept-source Optical Coherence TomographyChina
-
Eyegate Pharmaceuticals, Inc.CompletedPain, Postoperative | Cataract | Anterior Chamber InflammationUnited States
-
Nicole Fram M.D.CompletedIntraocular Pressure | Anterior Chamber Inflammation | Ocular Pain | Corneal Edema | Corneal Defect | Penetrating KeratoPlasty | Corneal TransplantUnited States
-
Asociación para Evitar la Ceguera en MéxicoCompletedAxial Length (AL) | Anterior Chamber Deep (ACD) | Lens Thickness (LT)Mexico
-
Nicole Fram M.D.CompletedCataract Senile | Anterior Chamber Inflammation | Ocular Pain | Corneal Edema | Corneal Defect | Penetrating KeratoPlasty | Nuclear Cataract | Cortical CataractUnited States
-
Iladevi Cataract and IOL Research CenterCompletedCataract Surgery | Shallow Anterior Chamber | PhacoemulsificationIndia
-
Zheng QianUnknownCataract | Shallow Anterior Chamber | Narrow AngleChina
-
Haag-Streit AGUniversity Hospital, Basel, SwitzerlandCompletedOptical Biometry of the Human Eye | General Analysis of the Anterior Chamber of the Human EyeSwitzerland
Clinical Trials on Prednisolone Acetate 1% Oph Susp
-
Prism Vision GroupCompleted
-
University of UtahCompletedCorneal Opacity | Intraocular PressureUnited States
-
Baylor Research InstituteNot yet recruitingMacula Edema | Cataract Diabetic
-
Bausch & Lomb IncorporatedCompletedInflammation | Conjunctivitis, Seasonal Allergic | Conjunctivitis, Giant PapillaryKorea, Republic of
-
SR Cornea ConsultantsCompleted
-
The New York Eye Surgery CenterOcular Therapeutix, Inc.TerminatedGlaucoma | CataractUnited States
-
The Cleveland ClinicOcular Therapeutix, Inc.Enrolling by invitationOcular Inflammation | Post-operative Pain | Vitreoretinal Surgery | Post-Operative InflammationUnited States
-
Peking UniversityRecruitingPosner Schlossman SyndromeChina
-
Nicole Fram M.D.CompletedIntraocular Pressure | Anterior Chamber Inflammation | Ocular Pain | Corneal Edema | Corneal Defect | Penetrating KeratoPlasty | Corneal TransplantUnited States
-
Actavis Inc.Completed